This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kees, U. R. Search for Related Content PubMed PubMed Citation Articles by Kees, U. R.

Resistance to 1-ß-D-Arabinofuranosylcytosine after High-Dose Treatment in Childhood Lymphoblastic Leukemia: Isolation of a Drug Resistant and a Sensitive Cell Line¹

Leukaemia Research Laboratory, Clinical Immunology Research Unit, Princess Margaret Hospital, G. P. O. Box D184, Perth, Western Australia 6001, Australia

A patient with acute lymphoblastic leukemia refractory to conventional combination chemotherapy schedules was treated with high-dose 1-ß-D-arabinofuranosylcytosine (ara-C) (8 doses of 3 g/m²). The patient achieved complete remission but relapsed 6 weeks later. Two cell lines, PER-145 and PER-163, were established from bone marrow samples obtained before and after treatment, respectively. Both cells represent common acute lymphoblastic leukemia cells (CALLA⁺, HLA-DR⁺, sIg^-, cIg^-). Exposure of the two cell lines to ara-C in vitro revealed that the primary line PER-145 is susceptible to ara-C, while cell line PER-163 is more than 1000-fold more resistant (based on 50% inhibitory doses for growth in culture). Moreover, it was observed that ara-C concentrations from 1 to 33 µg/ml resulted in the stimulation of this cell line. Five weeks after his relapse the patient was given another high-dose ara-C course during which the blasts increased by a factor of 10, thus showing a response in vivo similar to that of the PER-163 cells in vitro. This pair of human acute lymphoblastic leukemia cells provides a unique opportunity to investigate the mechanisms underlying the acquired resistance and proliferative response to ara-C.

¹ Supported by the Children's Leukaemia Research Fund of the Princess Margaret Children's Medical Research Foundation, Perth, Australia. This is Publication 236 from the Clinical Immunology Research Unit.

Received 7/14/86. Revised 12/ 9/86. Accepted 3/ 6/87.

This article has been cited by other articles:

				U. R. Kees, J. Ford, M. Watson, A. Murch, M. Ringner, R. L. Walker, and P. Meltzer Gene Expression Profiles in a Panel of Childhood Leukemia Cell Lines Mirror Critical Features of the Disease Mol. Cancer Ther., July 1, 2003; 2(7): 671 - 677. [Abstract] [Full Text] [PDF]